| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/18/2008 | US20080311123 Compositions and methods for the therapy and diagnosis of breast cancer |
| 12/18/2008 | US20080311122 Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
| 12/18/2008 | US20080311121 Antibody antagonists of ve-cadherin without adverse effects on vascular permeability |
| 12/18/2008 | US20080311120 Autocrine growth factor receptor antibodies and methods |
| 12/18/2008 | US20080311119 Antibody formulations |
| 12/18/2008 | US20080311118 Vascular endothelial cell growth factor antagonists and uses thereof |
| 12/18/2008 | US20080311117 Antibodies against PD-1 and uses therefor |
| 12/18/2008 | US20080311116 Process for the Determination of Inflammatory Process and Pharmaceutical Compositions for the Treatment Thereof |
| 12/18/2008 | US20080311115 Atherosclerosis, rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure |
| 12/18/2008 | US20080311114 Use of morphogenic proteins to treat human disc disease |
| 12/18/2008 | US20080311113 Method for treating adamts-5-associated disease |
| 12/18/2008 | US20080311112 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
| 12/18/2008 | US20080311111 Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 |
| 12/18/2008 | US20080311110 Chimeric Vaccine for Haemophilus Influenzae-Induced Disease |
| 12/18/2008 | US20080311109 Nucleotide sequences coding tumor polypeptides for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 12/18/2008 | US20080311108 Polypeptides |
| 12/18/2008 | US20080311107 Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| 12/18/2008 | US20080311106 Product Comprising a C4bp Core Protein and a monomeric Antigen, and Its Use |
| 12/18/2008 | US20080311078 Self-Buffering Protein Formulations |
| 12/18/2008 | US20080311043 Uses and compositions for treatment of psoriatic arthritis |
| 12/18/2008 | US20080311040 METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| 12/18/2008 | US20080311034 Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function |
| 12/18/2008 | CA2693958A1 Chemically modified peptides with improved immunogenicity |
| 12/18/2008 | CA2690858A1 Reduced-mass, long-acting dosage forms |
| 12/18/2008 | CA2690124A1 C3b antibodies and methods for the prevention and treatment of complement-associated disorders |
| 12/18/2008 | CA2690067A1 Diagnostic method |
| 12/18/2008 | CA2688256A1 Methods of modulating inflammation and compositions therefore |
| 12/18/2008 | CA2687896A1 Inhibitors of receptor tyrosine kinases and methods of use thereof |
| 12/18/2008 | CA2687123A1 Method for the treatment of atopic eczema |
| 12/18/2008 | CA2685066A1 Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic fhv-1 infections, and preventing or treating conjunctivitis |
| 12/18/2008 | CA2684699A1 Intradermal influenza vaccine |
| 12/18/2008 | CA2683287A1 Novel glycosylated peptide target in neoplastic cells |
| 12/18/2008 | CA2681454A1 Raccoon poxvirus expressing rabies glycoproteins |
| 12/18/2008 | CA2667788A1 Staphylococcus aureus specific anti-infectives |
| 12/18/2008 | CA2662921A1 Vaccine and pharmaceutical compositions and kits and uses thereof in stimulating an immune response with a synthetic glucopyranosyl lipid adjuvant |
| 12/17/2008 | EP2003203A1 Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
| 12/17/2008 | EP2003202A2 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 12/17/2008 | EP2003201A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 12/17/2008 | EP2002827A2 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 12/17/2008 | EP2002263A2 Cancer immunotherapy compositions and methods of use |
| 12/17/2008 | EP2001907A2 Methods and compositions for antagonism of rage |
| 12/17/2008 | EP2001516A2 Vaccine for viruses that cause persistent or latent infections |
| 12/17/2008 | EP2001510A2 Methods of treating lupus using cd4 antibodies |
| 12/17/2008 | EP2001509A1 Pharmaceuticals for influencing the reaction of the human immune system |
| 12/17/2008 | EP2001508A2 Covalently-linked complexes of hiv tat and env proteins |
| 12/17/2008 | EP2001507A2 Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/diagnostic use |
| 12/17/2008 | EP2001506A2 Vaccine against streptococcus agalactiae infection using native or recombinant s. agalactiae glyceraldheyde-3-phosphate dehydrogenase (gapdh) as a target antigen |
| 12/17/2008 | EP2001502A1 Parenteral low dose type 1 interferons for bladder cancer |
| 12/17/2008 | EP2001492A1 A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same |
| 12/17/2008 | EP2001490A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 12/17/2008 | EP2001459A2 Methods and compositions for inducing an immune response to hiv and models for testing |
| 12/17/2008 | EP2001285A2 Compositions and methods for controlling a honey bee parasitic mite |
| 12/17/2008 | EP1614426B1 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same |
| 12/17/2008 | EP1536778B1 Proteins binding to cross-beta structure comprising amyloid and methods for modulation of the cross-beta structure, its formation and its associated toxicity |
| 12/17/2008 | EP1322669B1 Stabilisation of immunoglobulins at low pH by adding cereals or oatmeal soup or oat flour |
| 12/17/2008 | EP1230214B1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 12/17/2008 | EP1024829B1 Tolerogenic fragments of natural allergens |
| 12/17/2008 | EP1007696B1 Il-13 receptor specific chimeric proteins and uses thereof |
| 12/17/2008 | EP0975810B1 Method of pcr testing of pooled blood samples |
| 12/17/2008 | EP0909317B1 Compositions for modulating the length of telomeres |
| 12/17/2008 | EP0791067B1 Protein kinase npk-110 |
| 12/17/2008 | CN101326195A 抗il-17抗体 Anti-il-17 antibody |
| 12/17/2008 | CN101325972A A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| 12/17/2008 | CN101325971A CTLA-4 antibody dosage escalation regimens |
| 12/17/2008 | CN101325970A 抗cd40抗体的应用 Application of anti-cd40 antibody |
| 12/17/2008 | CN101325969A Method of using IL6 antagonists with proteasome inhibitors |
| 12/17/2008 | CN101325968A Anti-CTLA-4 antibody compositions |
| 12/17/2008 | CN101325967A Influenza vaccines with reduced amount of emulsion adjuvant |
| 12/17/2008 | CN101325966A Functional influenza virus like particles (VLP) |
| 12/17/2008 | CN101322844A Non-virus non-structural protein foot-and-mouth disease vaccine and preparation thereof |
| 12/17/2008 | CN101322843A Staphylococcus aureus immunity composition |
| 12/17/2008 | CN101322842A Recombinant Staphylococcus aureus enterotoxin G oral preparation and use |
| 12/17/2008 | CN101322841A Recombinant Staphylococcus aureus enterotoxin J oral preparation and use |
| 12/17/2008 | CN100443503C Humanized CTLA-4 single chain antibody and human perforin path formed peptide P34 recombinant immunotoxin |
| 12/17/2008 | CN100443502C Vitellus immune globulin for preventing prawn virus, tis preparing method and use thereof |
| 12/17/2008 | CN100443118C Dosages for treatment with anti-ErbB2 antibodies |
| 12/17/2008 | CN100443117C Hepatitis B treating vaccine prepn and its prepn process and use |
| 12/17/2008 | CN100443116C Compositions and methods for treating or preventing pneumococcal infection |
| 12/16/2008 | US7465794 genetic engineered RNA viruses that express immunology modulators such as cytokines, chemokines, enzymes, cytokine and chemokine antagonist, surface receptors, adhesion molecule or ligands; genetic vaccines |
| 12/16/2008 | US7465790 Therapeutic antibodies |
| 12/16/2008 | US7465705 Immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies; diabetic neuropathy; brain injury, spinal cord injury |
| 12/16/2008 | US7465583 Comprising adeno-associated virus terminal repeat sequences; intrastrand base-pairing |
| 12/16/2008 | US7465580 vector encoding a derivative of EBNA-1 that is not cytotoxic when expressed efficiently in cells, which supports extrachromosomal replication, maintenance and transcription from extrachromosomal oriP containing vectors but does not substantially activate transcription from host cell genes |
| 12/16/2008 | US7465574 Recombinant RSV virus expression systems and vaccines |
| 12/16/2008 | US7465572 De-immunized streptokinase |
| 12/16/2008 | US7465553 Psoriasin expression by breast epithelial cells |
| 12/16/2008 | US7465464 Populations of cells that express flk-2 receptors |
| 12/16/2008 | US7465459 Piroplasmid vaccine |
| 12/16/2008 | US7465458 In situ administering Clostridium toxin; antiinflammatory agents |
| 12/16/2008 | US7465457 Method for preparing botulinum neurotoxin type A light chain |
| 12/16/2008 | US7465456 entirely from cloned cDNA; production of attenuated live influenza A and B virus suitable for vaccines, such as live virus vaccine formulations; increasing growth of a reassortant influenza virus in embryonated eggs |
| 12/16/2008 | US7465455 Lower immunotoxicity and having a high neutralization titer, veterinary medicine |
| 12/16/2008 | US7465454 Yeast-based vaccines as immunotherapy |
| 12/16/2008 | US7465452 Tumor antigen |
| 12/16/2008 | US7465451 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| 12/16/2008 | US7465450 Methods and compositions relating to anti-interleukin-4 receptor antibodies |
| 12/16/2008 | US7465449 Anti-αvβ6 antibodies |
| 12/16/2008 | US7465448 Chemokine receptor antagonists as therapeutic agents |
| 12/16/2008 | US7465447 Population of purified Fc-EPO fusion proteins for administration to mammal, proteins comprising Fc portion towards N-terminus and erythropoietin portion towards C-terminus, population having average of 11-28 sialic acid residues per purified Fc-EPO fusion protein; prolonged serum half-life; potency |
| 12/16/2008 | US7465446 Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |